N
Negar Hosseinkhani
Researcher at Tabriz University of Medical Sciences
Publications - 10
Citations - 158
Negar Hosseinkhani is an academic researcher from Tabriz University of Medical Sciences. The author has contributed to research in topics: Tumor microenvironment & Medicine. The author has an hindex of 3, co-authored 8 publications receiving 48 citations.
Papers
More filters
Journal ArticleDOI
Combination of Ipilimumab and Nivolumab in Cancers: From Clinical Practice to Ongoing Clinical Trials.
Omid Kooshkaki,Afshin Derakhshani,Negar Hosseinkhani,Mitra Torabi,Sahar Safaei,Oronzo Brunetti,Vito Racanelli,Nicola Silvestris,Behzad Baradaran +8 more
TL;DR: Data concerning the clinical activity and the adverse events of ipilimumab and nivolumab combination therapy is reviewed, assessing ongoing clinical trials to identify clinical outlines that may support combination therapy as an effective treatment.
Journal ArticleDOI
Immune Checkpoints and CAR-T Cells: The Pioneers in Future Cancer Therapies?
Negar Hosseinkhani,Afshin Derakhshani,Omid Kooshkaki,Mahdi Abdoli Shadbad,Khalil Hajiasgharzadeh,Amir Baghbanzadeh,Hossein Safarpour,Ahad Mokhtarzadeh,Oronzo Brunetti,Simon Yue,Nicola Silvestris,Behzad Baradaran +11 more
TL;DR: This review aims to provide recent findings of immune checkpoints, bispecific T-cell engagers, and CAR-T cells in cancer immunotherapy and discuss the pertained clinical trials.
Journal ArticleDOI
The Role of V-Domain Ig Suppressor of T Cell Activation (VISTA) in Cancer Therapy: Lessons Learned and the Road Ahead.
Negar Hosseinkhani,Afshin Derakhshani,Mahdi Abdoli Shadbad,Antonella Argentiero,Vito Racanelli,Tohid Kazemi,Ahad Mokhtarzadeh,Oronzo Brunetti,Nicola Silvestris,Behzad Baradaran +9 more
TL;DR: Wang et al. as mentioned in this paper reviewed the current evidence about the structure and expression pattern of VISTA, its role in TME, the clinicopathological significance, and its prognostic values in various cancers and proposed a strategy to overcome tumor immune-resistance states.
Journal ArticleDOI
A scoping review on the potentiality of PD-L1-inhibiting microRNAs in treating colorectal cancer: Toward single-cell sequencing-guided biocompatible-based delivery
Mahdi Abdoli Shadbad,Zahra Asadzadeh,Afshin Derakhshani,Negar Hosseinkhani,Ahad Mokhtarzadeh,Amir Baghbanzadeh,Khalil Hajiasgharzadeh,Oronzo Brunetti,Antonella Argentiero,Vito Racanelli,Nicola Silvestris,Behzad Baradaran +11 more
TL;DR: In this paper, a scoping review aimed to discuss the currently available evidence regarding the therapeutic potentiality of PD-L1-inhibiting microRNAs for colorectal cancer.
Journal ArticleDOI
A systematic review and meta-analysis on the significance of tigit in solid cancers: Dual tigit/pd-1 blockade to overcome immune-resistance in solid cancers.
Negar Hosseinkhani,Mahdi Abdoli Shadbad,Mohammad Asghari Jafarabadi,Noora Karim Ahangar,Zahra Asadzadeh,Seyede Momeneh Mohammadi,Parisa Lotfinejad,Nazila Alizadeh,Oronzo Brunetti,Rossella Fasano,Nicola Silvestris,Behzad Baradaran +11 more
TL;DR: Wang et al. as mentioned in this paper conducted a systematic review and meta-analysis based on the preferred reporting items for systematic reviews and metaanalysis (PRISMA) to determine its significance in patients with solid cancers, and they systematically searched the Web of Science, Embase, PubMed, and Scopus databases to obtain peer-reviewed studies published before September 20, 2020.